Home
Home

Arcalyst

3 Drugs Approved, but Only 1 Matters

3 Drugs Approved, but Only 1 Matters
Motley Fool

FDA rejects expanded use of Regeneron drug for gout

FDA rejects expanded use of Regeneron drug for gout
Reuters

Vivus, Onyx, Amarin Await Key Dates in July

Vivus, Onyx, Amarin Await Key Dates in July
Minyanville

Regeneron: FDA panel says no to Arcalyst for gout

Regeneron: FDA panel says no to Arcalyst for gout
Yahoo/AP

Pfizer, Gilead Sciences, Arena Pharmaceuticals Face Big Dates in May

Pfizer, Gilead Sciences, Arena Pharmaceuticals Face Big Dates in May
Minyanville

6 Biotech Stocks With Huge Potential In May

6 Biotech Stocks With Huge Potential In May
Seeking Alpha

News

Regeneron Announces Strong Results In Gout Study
Forbes

News

The Drug Passed, but the Stock Fell?
Motley Fool
»